|Bid||2.7600 x 1800|
|Ask||2.7700 x 1800|
|Day's range||2.6750 - 2.8100|
|52-week range||1.9400 - 10.8900|
|Beta (5Y monthly)||1.37|
|PE ratio (TTM)||9.20|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.57|
Endo (ENDP) stock gains following the settlement of three opioid cases in the New York State in exchange for a total payment of $50 million.
(Bloomberg) -- Endo International Plc’s debt rallied on Friday after the company settled claims by New York over its opioid marketing, averting a possible $1 billion verdict and the risk it could have been stripped of its legal defenses in an ongoing trial in the state. The pact, announced late Thursday, settles for $50 million allegations that the opioid maker’s sales and marketing efforts helped fuel a public crisis over the highly addictive painkillers. Lawyers for New York Attorney General L
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.